Sunovion Pharmaceuticals Inc.

Pgi Drug Discovery LLC

Sumitomo Pharma America, Inc.

Philip Glyn Jones

Linghong Xie

John Emmerson Campbell

Taleen G Hanania

Michael Charles Hewitt

Kerry Leigh Spear

Michele L R Heffernan

Noel Aaron Powell

Vadim Alexandrov

Scott C Malcolm

Robert Lew

Michele LR Heffernan

A molding device for producing thermoplastic articles and its method of use, wherein the molding device comprises a rigid bottom plate, a rigid top plate adapted to be removably coupled to the said bottom plate, a 3D-printed die or insert in the shape of half of the said article removably inserted into a CNC milled mold cavity. The molten thermoplastic material is injected in to the molding device through an injection port to form the thermoplastic in the shape of 3D-printed die or insert, wherein the thermoplastic article is a fishing lure.

Fishing lure injection molding using additive manufacturing

Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Compounds and compositions and uses thereof

Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, R, R, R, R, R, R, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders

Provided herein are substituted cyclopropane compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorders.

Substituted cyclopropanes as PDE-10 inhibitors

Provided herein are substituted [1,2,4]triazlolo[1,5-&#x3b1;]pyrazine compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorders.

Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.

D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders

Provided herein are substituted pyrazolopyridine compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors

Provided herein are Cyclic Nucleotide Phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

Substituted quinolines as PDE-10 inhibitors

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

Heteroaryl compounds and methods of use thereof

Provided herein are compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein 

Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors

Provided herein are compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is Rand Rtogether with the carbon atoms to which they are attached form a 1,2-phenylene ring optionally substituted with one or more R; L is &#x2014;C(R)&#x2014;C(R)&#x2014;; B is a heteroaromatic group defined herein; and -A-A- , A, Rand Rare defined herein. Also disclosed are methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

Growing community of inventors

Danvers, MA, United States of America

Philip Glyn Jones